Learn more

In this section, you will learn more about Gattefossé Pharmaceuticals expertise, through news, hot topics and publications at the cutting edge of science, you can browse through a library of on-demands webinars, and download our latest brochures.

News and hot topics

Women's medicines

  • Pharmaceuticals

Every woman faces a gynecological disorder at some point in her life, during puberty, maternity, menopause or post menopause. These age periods structure the women’s health market with treatments for menopause related disorders, postmenopausal osteoporosis, infertility, endometriosis, gynecological cancer and birth control.

Pediatric medicines

  • Pharmaceuticals

Pediatric patients have specific needs we have to take into account when developing formulations:
- need for dose flexibility to adapt to the body weight
- difficulty to swallow pills
- very sensitive to bitterness
- delicate skin

Focus on some solutions adapted to these specific challenges.

Smiling pediatric patient at the doctor's office

Formulating cannabinoids with lipid excipients

  • Cannabinoids

Cannabinoids are challenging drugs to formulate

cannabis plant in front of a lab technician
View more


Breaking boundaries in veterinary medicines

  • Lipid-based formulations
  • Animal Health

Part 1: The role of excipients in formulation success

Introduction to oral bioavailability enhancement using lipid excipients.

  • Lipid-based formulations

Part 2: Step by step development of successful lipid-based formulations


Latest Publications

In vivo confirmation of the permeation enhancement capacity of Labrafac™ MC60

  • Poster

Oct 2023

Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine

  • Scientific publication

May 2023

In this study, lipophilicity of insulin glargine (IG) was successfully increased via hydrophobic ion pairing (HIP) with sodium octadecyl sulfate to enable incorporation into self-emulsifying drug delivery systems (SEDDS). The SEDDS formulations F1 and F2 were administered to rats via oral gavage and resulted in a bioavailability of 0.55% and 0.44%, corresponding to a 7.7-fold and 6.2-fold increased bioavailability, respectively. Thus, incorporation of complexed insulin glargine into SEDDS formulations provides a promising approach to facilitate its oral absorption.

View more

All brochures

Gattefosse Brochure Safe and efficient skin drug delivery

  • Brochure

  • Topical/Transdermal
Gattefosse Brochure Safe and efficient skin drug delivery

Gelucire 44/14

  • Brochure

Learn how to use this self-emulsifying excipient to increase oral drug bioavailability

  • Oral
Download (.pdf - 2.14 MB)
View more